Please assess the completion status of the following clinical trial:

Trial Title: Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically-confirmed by central review CD30-positive nonlymphomatous malignancy~* Have failed, refused, or have been deemed ineligible for standard therapy~* Measurable disease~* Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0 or 1 or a Karnofsky or Lansky Performance Status score greater than or equal to 70~Exclusion Criteria:~* Primary diagnosis of lymphoma or central nervous system (CNS) malignancy~* History of another primary invasive malignancy that has not been definitively treated or in remission for at least 3 years~* Evidence of active cerebral/meningeal disease

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Brentuximab vedotin 1.8 mg/kg (Type: EXPERIMENTAL): Brentuximab vedotin 1.8 mg/kg every 3 weeks by IV infusion
- Brentuximab vedotin 2.4 mg/kg (Type: EXPERIMENTAL): Brentuximab vedotin 2.4 mg/kg every 3 weeks by IV infusion
- Brentuximab vedotin 1.2 mg/kg (Type: EXPERIMENTAL): Brentuximab vedotin 1.2 mg/kg weekly, 3 out of 4 weeks, by IV infusion

Based on this trial design, predict the completion outcome and termination type (if applicable).